1. Metcalfe D., Baram D., Mekori Y. 1997. Mast cells. Physiol. Rev. 77(4), 1033–1079.
2. He S.H. 2004. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J. Gastroenterol. 10, 10309–10318.
3. Galli S.J., Kalesnikoff J., Grimbaldeston M.A., Piliponsky A.M., Williams C.M.M., Tsai M. 2004. Mast cells as “Tunable” effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23(1), 749–786.
4. Umarova B.A., Lelekova T.V., Kopylova G.N., Goncharova E.L., Bakaeva Z.V., Samonina G.E. 2006. The protective effect of proline-containing peptides (PGP, PG, GP) on rat mesentery lymphatic vessels contractive activity disorders under experimental peritonitis. Bull. Exp. Biol. (Rus.) 142(9), 248–251.
5. Umarova B.A., Lelekova T.V., Kopylova G.N., Samonina G.E., Bakaeva Z.V., Goncharova E.L., Bondarenko N.S. 2009. The stabilization of mast cells decreases the disorders of lymphatic vessels functions under condition of inflammation. Cytokines and Inflammation. 8(3), 44–47.